A Powerful Alliance: Dexcom G7 Now Connects to Tandem t:slim X2
January 15 2024 - 3:30AM
Business Wire
- With more than 10 years of pioneering CGM market leadership in
AID integration, Dexcom is the most clinically studied‡‡ CGM brand
with AID capabilities and the clear choice for powering AID
systems1,2
- The clinically meaningful health outcomes that result from
using the t:slim X2 insulin pump with Control-IQ technology are
only proven when the system is connected to Dexcom CGM
technology3
- The power and accuracy of the Dexcom G7 is now combined with
the discretion of the Tandem t:slim X2 insulin pump and will begin
rolling out in countries across Europe and in South Africa from
today.
DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time
continuous glucose monitoring for people with diabetes, announced
today the Dexcom G7 Continuous Glucose Monitoring (CGM) System now
connects with the t:slim X2™ insulin pump by Tandem Diabetes Care
in countries across Europe and in South Africa. The announcement
comes just a month after the system launched in the United States
and combines the power and accuracy of Dexcom G7 with the
discretion of the Tandem t:slim X2.
“For over a decade Dexcom has been pioneering industry leading
CGM connectivity, meaning we have now safely powered AID systems
for more than 1 million patient years of cumulative use. It’s
therefore no wonder that Dexcom is the undisputed leader in CGM
connectivity and why our sensors are the clear choice for AID
systems,” said Jim Berkebile, Vice President Strategic Partners for
EMEA at Dexcom. “Moreover, the clinically meaningful health
outcomes that result from using the t:slim X2 insulin pump with
Control-IQ technology are proven only when the system is connected
to Dexcom CGM.”
Further solidifying Dexcom as the most studied CGM brand with
AID capabilities, new results from the COMISAIR seven-year follow
up – the longest prospective real-world CGM study ever conducted
and presented by Dr. Jan Soupal at EASD 2023 – showed significant
and continued reduction of HbA1c as well as a lower risk of the
development or progression of diabetic retinopathy associated with
the use of real-time CGM by people with Type 1 diabetes4.
Additionally, the COMISAIR seven-year follow up demonstrated
further substantial reduction in HbA1c when Dexcom CGM is connected
to the t:slim X2 insulin pump with Control-IQ technology5.
“AID systems offer life-changing technology to people living
with Type 1 diabetes,” said Dr. Emma Wilmot, Associate Professor,
University of Nottingham. “Empowering those living with diabetes to
manage their own condition and offering them the very best
technology we can is vital for diabetes care. We know that when
people combine real-time CGM and a pump to create an AID system
they spend more time in range, experience fewer incidences of
hypoglycaemia and enjoy greater peace of mind.”
Due to its 30 minute sensor warmup* the Dexcom G7 is the fastest
CGM connected to the t:slim X2 insulin pump, meaning that those
using a Dexcom G7 can spend more time benefiting from their AID
system than with any other CGM. Dexcom G7 users can also share
glucose data with loved ones and care teams in real time through
industry-leading remote monitoring capabilities.‡
“As we celebrate our 10-year partnership with Dexcom, we remain
committed to sustaining our rapid pace of innovation to further our
mission of helping improve the lives of people with diabetes around
the world,” said John Sheridan, President and Chief Executive
Officer of Tandem Diabetes Care. “We’re actively engaged with our
local distributors, supporting their efforts to make this exciting
new integration available for new customers and to existing t:slim
X2 pump users via remote software updates as quickly as
possible.”
Tandem is working with local distributors in the countries
listed below to support the launch of the t:slim X2 insulin pump
with Dexcom G7 integration and the delivery of remote software
updates for current eligible t:slim X2 users. Timing of new product
shipments and pump software updates will vary by country and will
take place throughout the first three months of 2024. Dexcom G7
integration with the t:slim X2 insulin pump will become available
in the following countries: Germany, the UK, Ireland, Sweden, South
Africa, Italy, Spain, Finland, Norway, Denmark, Slovakia, the Czech
Republic, Switzerland, Belgium, Luxembourg, and the
Netherlands.
To learn more and to get started with Dexcom G7 and the Tandem
t:slim X2 insulin pump, visit Dexcom.co.uk/tandem.
The launch of Dexcom G7 and the Tandem t:slim X2 insulin pump
further strengthens Dexcom’s position as the world’s most connected
CGM.4 With more than 60 connected partners worldwide, Dexcom is
committed to providing users with choice and flexibility when it
comes to how they view their glucose data and deliver insulin.§
About DexCom, Inc.
DexCom, Inc. empowers people to take real-time control of health
through innovative continuous glucose monitoring (CGM) systems.
Headquartered in San Diego, Calif., and with operations across
Europe and select parts of Asia/Oceania, Dexcom has emerged as a
leader of diabetes care technology. By listening to the needs of
users, caregivers, and providers, Dexcom works to simplify and
improve diabetes management around the world. For more information
about Dexcom CGM, visit www.dexcom.com.
‡‡ Dexcom CGM systems have been studied in over 50 registered
interventional clinical trials (clinicaltrials.gov). Dexcom, Data
on file 2023 *Dexcom G7 can complete warmup within 30 minutes,
whereas other CGM brands require up to an hour or longer. ‡Separate
Follow app and internet connection required. §Reference
www.dexcom.com/integrate.
1-2 Peacock S, et al. Diabetes Ther. 2023;14(5):839-855. 3
Dexcom, data on file, 2023. 4 Brown SA, et al. N Engl J Med.
2019;381(18):1707-1717. 5 Šoupal, J. Presented at EASD 2023,
Hamburg, Germany. October 2, 2023.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240115606690/en/
Media Contacts James
McIntosh 619-884-2118 james.mcintosh@dexcom.com
Gemma McDonald +44 7826 900639 gemma.mcdonald@dexcom.com
Investor Contact Sean
Christensen 858-203-6657 sean.christensen@dexcom.com
DexCom (NASDAQ:DXCM)
Historical Stock Chart
From Mar 2024 to Apr 2024
DexCom (NASDAQ:DXCM)
Historical Stock Chart
From Apr 2023 to Apr 2024